Anifrolumab

(Saphnelo®)

Saphnelo®

Drug updated on 11/15/2023

Dosage FormInjection (intravenous; 150 mg/mL)
Drug ClassType I interferon receptor antagonists
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE), who are receiving standard therapy.